Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Açın
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0,21%
1.091,51
-2,30
-0,21%
—1.093,811.096,521.100,221.091,51——
SIXC
Communications
SIXC
Communications
SIXC
+0,22%
610,11
+1,34
+0,22%
—608,77608,77612,97608,77——
SIXE
Energy
SIXE
Energy
SIXE
-1,34%
1.237,98
-16,83
-1,34%
—1.254,811.253,011.253,871.226,33——
SIXI
Industrials
SIXI
Industrials
SIXI
-0,93%
1.744,71
-16,40
-0,93%
—1.761,111.764,271.766,881.744,71——
SIXM
Financials
SIXM
Financials
SIXM
-0,37%
640,18
-2,40
-0,37%
—642,58644,87648,48640,18——
SIXR
Staples
SIXR
Staples
SIXR
-0,18%
849,58
-1,55
-0,18%
—851,13855,66858,75845,56——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0,23%
217,48
-0,50
-0,23%
—217,98217,98218,65216,88——
SIXT
Technology
SIXT
Technology
SIXT
+1,52%
3.260,69
+48,86
+1,52%
—3.211,833.227,213.268,383.226,55——
SIXU
Utilities
SIXU
Utilities
SIXU
-0,69%
942,45
-6,53
-0,69%
—948,98948,58957,83941,97——
SIXV
Health care
SIXV
Health care
SIXV
-0,52%
1.466,80
-7,72
-0,52%
—1.474,521.479,031.481,041.466,80——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0,22%
2.397,50
+5,38
+0,22%
—2.392,122.396,952.421,222.382,32——
4507:TYO
Shionogi & Co Ltd
3.128,00 JP¥
-1,32%
(-42,00) 1D
1 may, 15:30:00 GMT+9  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 4507...
Açın
3.172 JP¥
High
3.174 JP¥
Low
3.112 JP¥
Mkt. cap
2,78 trln
Avg. vol.
2,82 mln
Volume
2,33 mln
Dividend
2,11%
Quarterly dividend
16 JP¥
Ex dividend date
29 sen 2025
P/E ratio
13,66
52-wk high
3.758 JP¥
52-wk low
2.162 JP¥
EPS
229 JP¥
Shares outstanding
314,50 mln
No. of employees
5K
News stories
From sources across the web
Profile
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana. Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines. In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan. Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV. The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index. In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m. Wikipedia
About Shionogi & Co Ltd
CEOIsao Teshirogi
Employees4,96K
Founded1878
HeadquartersOsaka, Osaka, Yaponiya
SectorPharmaceutical industry
Websiteshionogi.com
Last report
30 yan 2026
Fiscal Period
Q3 2026
Normalized EPS / Estimate
-/ -JPY
Revenue / Estimate
147,72 mlrd/ (137,88 mlrd est.)JPY
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glanceInsights from the latest news and reports
Previous reportsAll values in JPY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in JPY
mar 2025
iyn 2025
sen 2025
dek 2025
Revenue
104,67 mlrd
99,78 mlrd
113,18 mlrd
147,72 mlrd
Cost of goods sold
17,79 mlrd
12,32 mlrd
16,94 mlrd
25,09 mlrd
Cost of revenue
17,79 mlrd
12,32 mlrd
16,94 mlrd
25,09 mlrd
Research and development expenses
29,16 mlrd
24,89 mlrd
27,55 mlrd
29,87 mlrd
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
23,87 mlrd
25,82 mlrd
27,56 mlrd
35,27 mlrd
Operating expense
56,78 mlrd
52,37 mlrd
56,57 mlrd
48,45 mlrd
Total operating expenses
74,57 mlrd
64,68 mlrd
73,51 mlrd
73,54 mlrd
Operating income
30,10 mlrd
35,10 mlrd
39,67 mlrd
74,18 mlrd
Other non operating income
-1,14 mlrd
-1,00 mln
-
-1,00 mln
EBT including unusual items
44,87 mlrd
46,33 mlrd
52,06 mlrd
92,89 mlrd
EBT excluding unusual items
53,35 mlrd
46,33 mlrd
52,06 mlrd
93,10 mlrd
Income tax expense
8,68 mlrd
6,98 mlrd
7,87 mlrd
18,21 mlrd
Effective tax rate
19,33%
15,07%
15,12%
19,60%
Other operating expenses
-2,00 mlrd
1,17 mlrd
979,00 mln
-17,25 mlrd
Net income
36,63 mlrd
39,36 mlrd
44,19 mlrd
74,68 mlrd
Net profit margin
35,00%
39,44%
39,04%
50,56%
Earnings per share
-
-
-
-
Interest and investment income
25,40 mlrd
13,56 mlrd
14,21 mlrd
20,53 mlrd
Interest expense
-
-2,33 mlrd
-1,82 mlrd
-1,61 mlrd
Net interest expenses
25,40 mlrd
11,23 mlrd
12,38 mlrd
18,92 mlrd
Depreciation and amortization charges
-3,26 mlrd
-
-485,00 mln
-
EBITDA
35,30 mlrd
40,11 mlrd
44,83 mlrd
80,21 mlrd
Gain or loss from assets sale
254,00 mln
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer